116 related articles for article (PubMed ID: 12948051)
1. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France.
Bernard LM; Althin R; Dhawan R; Grima DT; Lam A; Aballéa S
Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S30-43. PubMed ID: 12948051
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
[TBL] [Abstract][Full Text] [Related]
3. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
Rouland JF; Le Pen C; Benhaddi H; Piriou E; Lilliu H; Kenigsberg PA;
Eur J Ophthalmol; 2005; 15(5):562-80. PubMed ID: 16167287
[TBL] [Abstract][Full Text] [Related]
4. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.
Rouland JF; Le Pen C;
Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S5-20. PubMed ID: 12948049
[TBL] [Abstract][Full Text] [Related]
5. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.
Peeters A; Schouten JS; Severens JL; Hendrikse F; Prins MH; Webers CA
Acta Ophthalmol; 2012 Mar; 90(2):146-54. PubMed ID: 20731623
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.
Schwartz GF; Reardon G
Surv Ophthalmol; 2004; 49(6):621-3; author reply 623-4. PubMed ID: 15530957
[No Abstract] [Full Text] [Related]
7. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
Orme M; Collins S; Loftus J
J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
[TBL] [Abstract][Full Text] [Related]
8. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension.
Stewart WC; Leech J; Sharpe ED; Kulze J; Ellyn J; Day DG
Am J Manag Care; 2002 Aug; 8(10 Suppl):S240-8. PubMed ID: 12188166
[TBL] [Abstract][Full Text] [Related]
9. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension.
Day DG; Schacknow PN; Sharpe ED; Ellyn JC; Kulze JC; Threlkeld AB; Jones ED; Brown RH; Jenkins JN; Stewart WC
J Ocul Pharmacol Ther; 2004 Oct; 20(5):383-92. PubMed ID: 15650513
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.
Payet S; Denis P; Berdeaux G; Launois R
Clin Drug Investig; 2008; 28(3):183-98. PubMed ID: 18266403
[TBL] [Abstract][Full Text] [Related]
11. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.
Kobelt G; Jönsson L; Gerdtham U; Krieglstein GK
Graefes Arch Clin Exp Ophthalmol; 1998 Nov; 236(11):811-21. PubMed ID: 9825256
[TBL] [Abstract][Full Text] [Related]
12. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.
Walt JG; Lee JT
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S36-44. PubMed ID: 15016560
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.
Hommer A; Wickstrøm J; Friis MM; Steeds C; Thygesen J; Ferreras A; Gouws P; Buchholz P
Curr Med Res Opin; 2008 Apr; 24(4):1057-63. PubMed ID: 18315942
[TBL] [Abstract][Full Text] [Related]
16. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
17. Treatment of glaucoma in clinical practice: four-year results from a patient registry in France.
Kobelt G; Texier-Richard B; Buchholz P; Bron A; Renard JP; Rouland JF; Nordmann JP
J Glaucoma; 2010 Mar; 19(3):199-206. PubMed ID: 19661825
[TBL] [Abstract][Full Text] [Related]
18. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
[TBL] [Abstract][Full Text] [Related]
19. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension.
Fiscella R; Walt J
Drugs Aging; 2006; 23(1):39-47. PubMed ID: 16492068
[TBL] [Abstract][Full Text] [Related]
20. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study.
Diestelhorst M; Schaefer CP; Beusterien KM; Plante KM; Fain JM; Mozaffari E; Dhawan R
Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S21-9. PubMed ID: 12948050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
